Skip to contentM
Medifast Inc
M
MEDMedifast Inc Q3 2024 · 10-Q
Revenue$140.16M$140.16M−40.6% vs Q3 2023 Net Income$1.13M$1.13M−95.1% vs Q3 2023 EPS Diluted$0.10$0.10−95.3% vs Q3 2023 Gross Profit$105,674,000−40.4% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Medifast Inc · CIK 910329 · Engraved from SEC EDGAR
Operating Cash Flowderived$9,072,000−69.7% Free Cash Flowderived$7,682,000−72.8% Margins · derivedGross margin75.4%+0.2 pt vs Q3 2023
Operating margin1.5%−9.3 pt vs Q3 2023
Net margin0.8%−9.0 pt vs Q3 2023
ended Sep 30, 2024 · filed Nov 4, 2024 · 35 d after period end